Esteva FJ - Search Results

1

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.

Esteva FJ, Katz E. Esteva FJ, et al. JCO Oncol Pract. 2024 Mar 12:OP2300563. doi: 10.1200/OP.23.00563. Online ahead of print. JCO Oncol Pract. 2024. PMID: 38471052 Review.

2

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Zimmerman BS, Esteva FJ. Zimmerman BS, et al. Among authors: esteva fj. Cancers (Basel). 2024 Feb 16;16(4):800. doi: 10.3390/cancers16040800. Cancers (Basel). 2024. PMID: 38398191 Free PMC article. Review.

3

Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study.

He X, Ji J, Qdaisat A, Esteva FJ, Yeung SJ. He X, et al. Among authors: esteva fj. Lancet Reg Health Am. 2024 Mar 8;32:100712. doi: 10.1016/j.lana.2024.100712. eCollection 2024 Apr. Lancet Reg Health Am. 2024. PMID: 38495316 Free PMC article.

4

Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer.

Esteva FJ, Hortobagyi GN. Esteva FJ, et al. Oncologist. 1998;3(5):300-313. Oncologist. 1998. PMID: 10388120

5

A new paradigm for classifying and treating HER2-positive breast cancer.

He X, Yeung SJ, Esteva FJ. He X, et al. Among authors: esteva fj. Cancer Rep (Hoboken). 2023 Aug;6(8):e1841. doi: 10.1002/cnr2.1841. Epub 2023 May 31. Cancer Rep (Hoboken). 2023. PMID: 37254964 Free PMC article. Review.

6

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.

Burris HA, Chan A, Bardia A, Thaddeus Beck J, Sohn J, Neven P, Tripathy D, Im SA, Chia S, Esteva FJ, Hart L, Zarate JP, Ridolfi A, Lorenc KR, Yardley DA. Burris HA, et al. Among authors: esteva fj. Br J Cancer. 2021 Aug;125(5):679-686. doi: 10.1038/s41416-021-01415-9. Epub 2021 Jun 22. Br J Cancer. 2021. PMID: 34158598 Free PMC article. Clinical Trial.

7

Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors.

He X, Ji J, Dai X, Qdaisat AZ, Esteva FJ, Hortobagyi GN, Yeung SJ. He X, et al. Among authors: esteva fj. Clin Cancer Res. 2021 Oct 1;27(19):5343-5352. doi: 10.1158/1078-0432.CCR-20-4162. Clin Cancer Res. 2021. PMID: 34117035

8

Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis.

Failler M, Giro-Perafita A, Owa M, Srivastava S, Yun C, Kahler DJ, Unutmaz D, Esteva FJ, Sánchez I, Dynlacht BD. Failler M, et al. Among authors: esteva fj. Mol Biol Cell. 2021 Jan 15;32(2):169-185. doi: 10.1091/mbc.E20-02-0111. Epub 2020 Nov 18. Mol Biol Cell. 2021. PMID: 33206585 Free PMC article.

9

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.

Fasching PA, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, Pivot X, Bianchi GV, Martin M, Chandiwana D, Lanoue B, Ridolfi A, Wang Y, Rodriguez Lorenc K, Nusch A. Fasching PA, et al. Among authors: esteva fj. Breast. 2020 Dec;54:148-154. doi: 10.1016/j.breast.2020.09.008. Epub 2020 Sep 23. Breast. 2020. PMID: 33065342 Free PMC article. Clinical Trial.

10

Validation of plasma metabolites associated with breast cancer risk among Mexican Americans.

Zhao H, Shen J, Ye Y, Wu X, Esteva FJ, Tripathy D, Chow WH. Zhao H, et al. Among authors: esteva fj. Cancer Epidemiol. 2020 Dec;69:101826. doi: 10.1016/j.canep.2020.101826. Epub 2020 Sep 30. Cancer Epidemiol. 2020. PMID: 33010726 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page